TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01448486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Oral raltegravir, 400 mg tablet, twice daily for one year.
Study: NCT00777608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo 5mg (run in)
Description: Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo 5mg (run in)
Description: Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5 - 10 mg
Description: Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo 5-10 mg
Description: Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Study: NCT04056286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 45 g whey protein + 20 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 45 g whey protein + 20 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-OHB/whey
Description: 50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
Study: NCT00777608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Description: Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil 10 mg
Description: Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
Study: NCT02109380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Study: NCT01594983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCQ908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCQ908
Study: NCT03318731

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Taken orally in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenugreek Extract, Low Dose
Description: Taken orally in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenugreek Extract, High Dose
Description: Taken orally in capsule form
Study: NCT03630250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N. lactamica
Description: Genetically modified N. lactamica

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N. lactamica
Description: Genetically modified N. lactamica
Study: NCT03473626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alicaforsen
Description: Alicaforsen tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alicaforsen
Description: Alicaforsen tablet
Study: NCT04105322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
Study: NCT03510910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 600 mg to be taken every 8 hours (TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percocet
Description: Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percocet
Description: Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN
Study: NCT04247789

Intervention type: OTHER
Intervention: Self-reported questionairres
Description: the fatigue will be determined through self reported questionnairres
Study: NCT01594983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate once daily 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Fish Oil once daily for 12 weeks
Study: NCT04180631

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound imaging parameter (QUS)
Description: Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
Study: NCT01064752

Intervention type: DRUG
Intervention: Minocycline
Description: 100 mg po bid for 8 weeks
Study: NCT03957252

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test: ClarityDX Prostate
Description: PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test: ClarityDX Prostate
Description: PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
Study: NCT02728570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dietary Flavonoids
Description: A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dietary Flavonoids
Description: A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
Study: NCT03406871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
Study: NCT02728570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dietary Flavonoids
Description: A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dietary Flavonoids
Description: A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
Study: NCT02092467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Oral tablet, 5 mg BID
Study: NCT03406871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
Study: NCT01594983

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908
Study: NCT04588298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally.
Study: NCT01594983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of fenofibrate
Description: Matching placebo of fenofibrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of fenofibrate
Description: Matching placebo of fenofibrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of fenofibrate
Description: Matching placebo of fenofibrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of fenofibrate
Description: Matching placebo of fenofibrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of fenofibrate
Description: Matching placebo of fenofibrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of fish oil
Description: Matching placebo of fish oil capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of fish oil
Description: Matching placebo of fish oil capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of fish oil
Description: Matching placebo of fish oil capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of fish oil
Description: Matching placebo of fish oil capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of fish oil
Description: Matching placebo of fish oil capsule
Study: NCT04339439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessel loop (FDA product code FZZ)
Description: The intervention will be a vessel loop placed below sutures to raise the sutures from the skin of the palm.
Study: NCT00779701

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
Study: NCT04568070

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mini-BESTest (Mini-Balance Evaluation Systems Test)
Description: Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Description: The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Timed Up and Go Test
Description: It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Reach Test
Description: The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
Study: NCT01145443

Intervention type: OTHER
Intervention: Alternative Intensivist staffing models.
Description: During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.

Intervention type: OTHER
Intervention: Alternative Intensivist staffing models.
Description: During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
Study: NCT00844714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
Study: NCT03039283

Intervention type: DEVICE
Intervention: Nucleus CI532 cochlear implant
Description: Retrospective study of the commercial CI532 cochlear implant
Study: NCT02469753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs
Description: continuous daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs
Description: on demand

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-TNF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-TNF
Study: NCT04580667

Intervention type: OTHER
Intervention: Collection of plasma samples
Description: Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
Study: NCT02614586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron capsule.
Study: NCT03950960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days
Study: NCT00946023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6 through -2: 30 mg/m\^2 IV daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 centigray (cGy) in a single fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start on Day 5 through Day 180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Day 30 and every week after for 8 total doses: 375 mg/m\^2 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplant (BMT)
Description: Day 0: Donor bone marrow infusion
Study: NCT03310905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Wall Transplant with another solid organ transplant
Description: Transplant of abdominal wall in combination with another solid organ transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Wall Transplant alone
Description: Abdominal Wall Transplant alone
Study: NCT02614586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching, solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching, solution.
Study: NCT03357770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL
Study: NCT03064269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
Study: NCT01598207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marinol
Description: 5mg BID, orally for 1 month
Study: NCT02614586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching, solution.
Study: NCT01598207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg BID, orally for 1 month
Study: NCT04176718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: predetermined dose, intravenously, at predetermined times per cycle
Study: NCT04176718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: predetermined dose, intravenously, give 3 times per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: predetermined dose, orally, daily per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: predetermined dose, orally, given 8 times per cycle
Study: NCT04273841

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Military Energy Gum
Description: Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gum
Description: Pellet form placebo gum
Study: NCT04280484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: 1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Hypoxia
Description: 1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
Study: NCT04127461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic endoscope
Description: The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic endoscope
Description: The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
Study: NCT02152982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02614586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching, solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching, solution.